ATRC240719C35000
- 0.03
- 0.000.00%
AtriCure Newsroom
AtriCure, Inc. (NASDAQ:ATRC) Might Not Be As Mispriced As It Looks
There wouldn't be many who think AtriCure, Inc.'s (NASDAQ:ATRC) price-to-sales (or "P/S") ratio of 2.8x is worth a mention when the median P/S for the Medical Equipment industry in the United States
AtriCure to Announce Second Quarter 2024 Financial Results
AtriCure, Inc. ((
Analyst Ratings For AtriCure
AtriCure (NASDAQ:ATRC) has been analyzed by 6 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish.The table below summarizes their recent ratings, show
AtriCure Price Target Maintained With a $40.00/Share by Needham
AtriCure Price Target Maintained With a $40.00/Share by Needham
Express News | Needham Reiterates Buy on AtriCure, Maintains $40 Price Target
AtriCure Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 07/08/2024 78.17% Needham $40 → $40 Reiterates Buy → Buy 05/02/2024 118.26% Canaccord Genuity $57 → $49 Ma
Needham Maintains AtriCure(ATRC.US) With Buy Rating, Maintains Target Price $40
Needham analyst Michael Matson maintains $AtriCure(ATRC.US)$ with a buy rating, and maintains the target price at $40.According to TipRanks data, the analyst has a success rate of 41.8% and a total
Atricure's Competitive Landscape Clears: A Buy Rating Amid Delayed Threats and Growth Prospects
AtriCure And Two Other Undervalued Small Caps With Insider Actions In The United States
AtriCure Leads Three Undervalued Small Caps With Insider Actions In United States
UBS Maintains AtriCure(ATRC.US) With Buy Rating, Cuts Target Price to $35
UBS analyst Danielle Antalffy maintains $AtriCure(ATRC.US)$ with a buy rating, and adjusts the target price from $58 to $35.According to TipRanks data, the analyst has a success rate of 51.3% and a to
AtriCure (ATRC) Stock Slipped on Competition Threat
AtriCure Up Over 14%, on Pace for Largest Percent Increase Since October 2016 -- Data Talk
AtriCure, Inc. (ATRC) is currently at $24.19, up $2.99 or 14.1% --Would be highest close since May 1, 2024, when it closed at $24.76 --On pace for largest percent increase since Oct. 28, 2016, when
12 Health Care Stocks Moving In Tuesday's Intraday Session
GainersMustang Bio (NASDAQ:MBIO) stock moved upwards by 50.0% to $1.12 during Tuesday's regular session. The company's market cap stands at $31.7 million. Sonoma Pharmaceuticals (NASDAQ:SNOA) shares i
Express News | Watching AtriCure; Traders Circulating Unconfirmed Rumor Suggesting Edwards Lifesciences Is Said To Mull Takeover Bid For The Co
AtriCure Gains Amid Report of Edwards Lifesciences Interest
An Intrinsic Calculation For AtriCure, Inc. (NASDAQ:ATRC) Suggests It's 48% Undervalued
Key Insights AtriCure's estimated fair value is US$39.98 based on 2 Stage Free Cash Flow to Equity AtriCure is estimated to be 48% undervalued based on current share price of US$20.97 The US$47.3
Is AtriCure, Inc. (NASDAQ:ATRC) Trading At A 48% Discount?
Insider Buying: Chief Technical Officer Salvatore Privitera Acquires Shares of AtriCure Inc (ATRC)
AtriCure(ATRC.US) Officer Buys US$111.25K in Common Stock
$AtriCure(ATRC.US)$ Officer Privitera Salvatore purchased 5,000 shares of common stock on May 30, 2024 at an average price of $22.25 for a total value of $111.25K.Source: Announcement What is statemen